Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | FES | P07332 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398988 | 0.91 | FGFR1 (0.55) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL12371121 | 0.90 | FGFR1 (0.67) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL12371383 | 0.86 | AURKA (0.48) | FGFR1KDRJAK2BTKEGFR | |
| SCHEMBL2267020 | 0.84 | JAK3 (0.65) | FGFR1KDRJAK2BTKEGFR | |
| SCHEMBL1674146 | 0.80 | PTK2 (0.72) | JAK2BRD4BTKEGFRFGFR2 | |
| SCHEMBL29848454 | 0.78 | FGFR1 (0.79) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL16514176 | 0.78 | FGFR1 (0.79) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL29847953 | 0.78 | FGFR1 (0.72) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL16515367 | 0.78 | FGFR1 (0.72) | FGFR1KDRJAK2BRD4BTK | |
| SCHEMBL16471413 | 0.77 | FGFR1 (0.56) | FGFR1KDRJAK2BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | FGFR1 69/4885KDR 414/4885JAK2 53/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | FGFR1 69/4885KDR 414/4885JAK2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.